• BRD4–RAC1 Co-targeting in Breast Cancer

  2026-09-01

  This 2021 study identifies combined BRD4 and RAC1 inhibition as a subtype-aware strategy for limiting breast-cancer growth, migration, stem-like behavior, and xenograft tumorigenesis. Its mechanistic contribution is the connection of BRD4–RAC1 blockade to disruption of the c-MYC–G9a–FTH1 axis and downregulation of HDAC1, providing a framework for interpreting BET inhibitor responses beyond c-MYC suppression alone.

• Anlotinib Hydrochloride: An Assay-First Guide

  2026-09-01

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor whose value in cancer research depends on connecting receptor potency with endothelial phenotypes, ERK signaling, and disease-relevant models. This assay-first guide translates molecular data and a rare-tumor case report into practical experimental decisions.

• Anlotinib Hydrochloride: Angiogenesis Mechanism

  2026-08-31

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor that blocks VEGFR2, PDGFRβ, and FGFR1 signaling. Peer-reviewed assays associate this anti-angiogenic small molecule with endothelial cell migration inhibition, capillary-like tube suppression, and ERK signaling pathway inhibition, supporting its use in cancer research.

• Tp47, PKM2, and Inflammatory Senescence

  2026-08-31

  The reference study identifies a mechanistic link between the Treponema pallidum protein Tp47, PKM2-dependent metabolic reprogramming, and inflammatory senescence in macrophages. Its findings connect pathogen-induced glycolytic changes with EIF2AK2 activation, NLRP3 inflammasome signaling, pyroptosis, and senescence-associated inflammatory output, providing a framework for interpreting senescent cell detection in infection models.

• Rocilinostat (ACY-1215): HDAC6 Research Guide

  2026-08-30

  Rocilinostat, also called ACY-1215, is a selective HDAC6 inhibitor with a reported biochemical IC50 of 5 nM. Preclinical multiple myeloma studies associate HDAC6 inhibition with increased α-tubulin acetylation, reduced tumor-cell viability, apoptosis, and enhanced proteasome-inhibitor activity.

• Tamsulosin: From Meta-Analysis to Assay Design

  2026-08-29

  Tamsulosin research is strongest when clinical effect sizes are translated into assay endpoints, stone-size strata, and exposure controls. This evidence-led guide connects α₁A pharmacology with reproducible ureteral, smooth-muscle, and translational study design.

• Venetoclax and Senescent Glioblastoma Cells After TMZ

  2026-08-28

  The reference study identifies a senescent cell anti-apoptotic program involving c-IAP2 and Bcl-2 after temozolomide exposure in glioblastoma models. Its key implication is that sequential inhibition with BV6 and venetoclax can selectively eliminate therapy-induced senescent cells, providing a framework for studying senolytic combinations rather than relying on additional DNA damage alone.

• Bromodomain Inhibitor, (+)-JQ1: Applied Workflows

  2026-08-28

  Bromodomain Inhibitor, (+)-JQ1 enables controlled BET chromatin perturbation across cancer, apoptosis, inflammation, and BRDT-focused reproductive biology. This practical guide connects mechanism to assay design, combination studies, storage, and troubleshooting for more reproducible results.

• Boc-D-FMK: A Mechanistic Guide to Caspase Control

  2026-08-27

  Boc-D-FMK is a cell-permeable pan-caspase inhibitor for dissecting apoptosis and inflammatory signaling. This guide connects its use in renal and hepatic models with a fibrosis study that clarifies how to distinguish pathway modulation from nonspecific loss of cell viability.

• PLAC1 in Clear Cell Renal Cell Carcinoma

  2026-08-27

  A 2025 Cellular Signalling study identifies PLAC1 as a prognostic biomarker and candidate molecular target in clear cell renal cell carcinoma (ccRCC). By combining TCGA analysis, patient-sample validation, PLAC1 knockdown, and high-throughput virtual screening, the authors nominate Amaronol B and Canagliflozin as compounds that reduce PLAC1 expression and ccRCC-associated progression in vitro.

• HBTU: From Coupling Chemistry to Peptide Design

  2026-08-26

  Explore how HBTU, a racemization-resistant coupling reagent, supports efficient peptide bond formation and reliable solid phase peptide synthesis. This article connects HBTU chemistry with assay design for enzyme-responsive peptide assemblies while separating synthesis evidence from therapeutic claims.

• Ionizing Radiation and Altered Neuronal Differentiation

  2026-08-26

  Eom et al. show that ionizing radiation does more than reduce neural stem-cell viability: it redirects neuronal differentiation in C17.2 mouse neural stem-like cells through PI3K-linked STAT3–mGluR1 and p53 signaling. The study combines morphology, neuronal marker analysis, neurotransmitter-related gene profiling, pharmacological inhibition, and primary-cell validation to connect radiation exposure with potentially abnormal neuronal function.

• Spatial Proteomics for Smarter Brain Probes

  2026-08-25

  This study develops therapeutic-loaded titania nanotube arrays as multifunctional coatings for intracortical microelectrodes and uses spatial proteomics to resolve local neuroinflammatory responses around the implant. The work provides design guidance for coating placement while linking antimicrobial control, localized drug release, neuronal preservation, and immune response modulation.

• 4-Hydroxytamoxifen: Protocols and QC

  2026-08-25

  4-Hydroxytamoxifen (SKU B6167) provides a DMSO-soluble estrogen receptor modulator for controlled in vitro and selected in vivo research workflows, including cancer models, apoptosis assays, and cardiac myocyte studies. It should not be selected for protocols that require aqueous or ethanol solubility, and its solid-state storage and vehicle controls require careful management.

• Lopinavir (A8204): Reliable Assay Design

  2026-08-24

  Learn how Lopinavir (SKU A8204) can support reproducible cell-based antiviral, viability, and cytotoxicity workflows. This scenario-driven guide connects HIV protease inhibition data with practical solvent, concentration, serum, interpretation, and vendor-selection decisions.

8178 records 5/546 page Previous Next 12345 下5页 Last page